Literature DB >> 10420166

Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period.

F Berrendero1, N Sepe, J A Ramos, V Di Marzo, J J Fernández-Ruiz.   

Abstract

Cannabinoid CB(1) receptors emerge early in the rat brain during prenatal development, supporting their potential participation in events related to neural development. In the present investigation, we completed earlier studies, analyzing CB(1) receptor binding and mRNA expression by using autoradiography and in situ hybridization, respectively, in the brain of rat fetuses at gestational day (GD) 21 and of newborns at postnatal days (PND) 1 and 5, in comparison with the adult brain. These analyses were paralleled by quantitation of levels of anandamide and its precursor, N-arachidonoyl-phosphatidylethanolamine (NAPE), and of 2-arachidonoyl-glycerol (2-AG), carried out by using gas chromatography / mass spectrometry of the tri-methyl-sylyl-ether derivatives. As expected, CB(1) receptor binding was detected at GD21 in a variety of brain structures. In most of them, such as the hippocampus, cerebral cortex, cerebellum, basal ganglia, and limbic nuclei, there were no marked differences in the density of CB(1) receptors in animals at GD21 as compared to early newborns (PND1 and 5), although it markedly increased in these regions in adulthood. However, with the exception of the cerebellum and, in part, the caudate-putamen, the pattern observed for binding in these regions was clearly different from that observed for mRNA expression of the CB(1) receptor, which currently exhibited the highest levels at PND1 and the lowest in the adult brain. This was also seen in the basolateral amygdaloid nucleus, ventromedial hypothalamic nucleus, medial habenula, and other structures. In the caudate-putamen and, particularly, in the cerebellum, mRNA expression was higher in the adult brain as compared with other ages. As previously reported, specific binding for CB(1) receptors was also detected at GD21 in white matter areas, such as the corpus callosum, anterior commissure, fornix, fimbria, stria medullaris, stria terminalis, and fasciculus retroflexum. With the exception of the anterior commissure and the fimbria, specific binding progressively decreased at PND1 and PND5 until disappearing in the adult brain. In the fimbria, the highest values of binding were seen at PND1, but binding also completely disappeared in the adult brain, whereas in the anterior commissure, specific binding at PND1 and PND5 was lesser than that observed at GD21 and, particularly, in adulthood. CB(1) receptor mRNA expression was not detected in these white matter areas, thus dismissing the possible presence of these receptors in glial cells rather than in neuronal axons. However, mRNA expression was detected in the brainstem, an area also rich in white matter, and it mostly correlated with receptor binding, exhibiting a progressive decrease from GD21 up to adulthood. CB(1) receptor mRNA expression was also detected at GD21 in atypical areas where binding was not detected. These areas are proliferative regions, such as the subventricular zones of the neocortex, striatum, and nucleus accumbens. This atypical location only persisted at PND1 and PND5 in the striatal subventricular zone, but disappeared in the adult brain. We also found measurable levels of different endogenous cannabinoids in the developing brain. High levels of 2-AG, comparable to those found in the adult brain, were measured at GD21, whereas significantly lower levels were measured for anandamide and NAPE at this fetal age compared with the levels found in the adult brain. Levels of anandamide and NAPE increased during the early postnatal period until reaching the maximum in the adult brain. By contrast, 2-AG levels peaked at PND1, with values approximately twofold higher than those found at the other ages. In summary, all these data demonstrate that the endogenous cannabinoid system, constituted by endogenous ligands and receptor signaling pathways, is present in the developing brain, which suggests a possible specific role of this system in key processes of neural development. (c) 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10420166     DOI: 10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO;2-R

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  84 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

2.  Neuroimaging of prenatal drug exposure.

Authors:  Diana L Dow-Edwards; Helene Benveniste; Marylou Behnke; Emmalee S Bandstra; Lynn T Singer; Yasmin L Hurd; L R Stanford
Journal:  Neurotoxicol Teratol       Date:  2006 May-Jun       Impact factor: 3.763

3.  Cannabinoid receptor 1 signaling in embryo neurodevelopment.

Authors:  Delphine Psychoyos; K Yaragudri Vinod; Jin Cao; Shan Xie; Richard L Hyson; Bogdan Wlodarczyk; Weimin He; Thomas B Cooper; Basalingappa L Hungund; Richard H Finnell
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2012-02-06

Review 4.  Role of the endocannabinoid system in vertebrates: Emphasis on the zebrafish model.

Authors:  Francesca Oltrabella; Adam Melgoza; Brian Nguyen; Su Guo
Journal:  Dev Growth Differ       Date:  2017-05-17       Impact factor: 2.053

5.  An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.

Authors:  Giulio G Muccioli; Nephi Stella
Journal:  Anal Biochem       Date:  2007-09-29       Impact factor: 3.365

6.  Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.

Authors:  Lei Wang; Jie Liu; Judith Harvey-White; Andreas Zimmer; George Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 7.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

8.  Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats.

Authors:  Viviana Trezza; Patrizia Campolongo; Tommaso Cassano; Teresa Macheda; Pasqua Dipasquale; Maria Rosaria Carratù; Silvana Gaetani; Vincenzo Cuomo
Journal:  Psychopharmacology (Berl)       Date:  2008-05-02       Impact factor: 4.530

9.  Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions.

Authors:  Panayotis K Thanos; Roberto C Ramalhete; Michael Michaelides; Yianni K Piyis; Gene-Jack Wang; Nora D Volkow
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

10.  CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/glycogen synthase kinase-3beta/beta-catenin signaling.

Authors:  Stefania Trazzi; Martin Steger; Valentina Maria Mitrugno; Renata Bartesaghi; Elisabetta Ciani
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.